Bengaluru based HealthCare Global Enterprises Limited (HCG Cancer Hospital Bengaluru) and Strand Life Sciences has recently launched comprehensive genomic profiling (CGP), an approach to detect multiple actionable cancer biomarkers at ‘one go’ to optimize treatment for better clinical outcomes.

HCG has joined hands with Strand to develop StrandAdvantage500, a simple and comprehensive Next Generation Sequencing (NGS) based assay that analyses cancer-relevant genetic alterations from DNA and RNA derived from a patient’s tumor in one integrated workflow.

Speaking about the launch, Dr. B.S. Ajaikumar, Chairman and CEO, HCG Enterprises Ltd., said, “Cancer cases in India are on the rise, and the goal is to offer affordable as well as right cancer care.   We have witnessed instances where patients do not respond to certain drugs due to their heterogeneous genetic makeup. Partnering with Strand and Illumina, we have been diligently profiling our patients to understand their genomic makeup and manage them accordingly. However, with CGP based tumor profiling, we will have consolidated cancer-relevant biomarker detection to understand more actionable genetic alterations upfront.”

Comprehensive genomic profiling with StrandAdvantage500 will overcome the challenge of iterative testing with limited biopsy samples and enable us to consolidate the detection of biomarkers into a single assay, thus saving precious biopsy samples, reducing the need of rebiopsy and provides faster and comprehensive results. This innovative approach will help in managing the disease better and design treatment with best possible clinical outcomes.